Clinical Trial Applications: Filter, Search, and view applications
# | Protocol No | Study Title | Investigator(s) & Site(s) | |
---|---|---|---|---|
366. |
ECCT/18/12/01 | study to determine if a new malaria vaccine is safe and induces immunity among Kenyan adults, young children and infants. A Phase 1b, open-label, age de-escalation, dose-escalation study to evaluate the safety and immunogenicity of different doses of a candidate malaria vaccine; adjuvanted R21(R21/MM) in adults, young children and infants in Kilifi, Kenya. |
Principal Investigator(s) 1. Mainga Hamaluba Site(s) in Kenya KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (CGMRC), Kilifi, Kenya. |
View |
367. |
ECCT/19/11/01 | A study to determine if candidate malaria vaccines are safe, effective, and induce immunity among Kenyan adults. Safety, immunogenicity, and efficacy of R21/Matrix M (R21/MM) and ChAd63/MVA-ME-TRAP in the context of controlled human malaria infection: A Phase IIb Trial in Kenyan Adults. |
Principal Investigator(s) 1. Melissa Kapulu Site(s) in Kenya KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (CGMRC), Kilifi, Kenya. |
View |
368. |
ECCT/23/07/01 | POWWeR Health Study Single arm trial of menstrual cups among economically vulnerable women to reduce Bacterial vaginosis and STIs through reduced harmful sexual and menstrual practices (POWWeR Health Study): A Phase 2 Trial |
Principal Investigator(s) 1. Fredrick Otieno 2. Supriya Dinesh Mehta Site(s) in Kenya Nyanza Reproductive Health Society |
View |
369. |
ECCT/22/08/03 | NeoSep1 An open-label randomised controlled trial comparing novel combination and currently used antibiotic regimens for the empiric treatment of clinically diagnosed neonatal sepsis with a run-in confirmatory pharmacokinetic phase. |
Principal Investigator(s) 1. Christina Wesonga Obiero 2. James Alexander Berkley Site(s) in Kenya 1. Kilifi County Hospital, KEMRI- Wellcome Trust Research Programme (KWTRP) (Kilifi county) |
View |
370. |
ECCT/23/06/08 | TSCV3000 Age-descending, randomized, placebo-controlled Phase 2 trial in three sites in sub-Saharan Africa to assess the safety and immunogenicity of a parenteral Trivalent Salmonella (S. Enteritidis/S. Typhimurium/S. Typhi Vi) Conjugate Vaccine (TSCV) versus placebo |
Principal Investigator(s) 1. RICHARD ONYANDO OMORE Site(s) in Kenya 1. SIAYA COUNTY REFERRAL HOSPITAL (Siaya county) 2. ST. ELIZABETH LWAK HOSPITAL (Siaya county) |
View |